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PTEN Expression in Primary Prostate Carcinoma in
Turkish Patients*
Aim: Prostatic adenocarcinoma shows remarkable variability in the incidence and biological behavior between
populations from different races and geographical regions of the world. PTEN has been reported as the most
commonly mutated tumor suppressor gene in prostate cancer. Incidence of PTEN alterations occurring in
prostatic carcinoma has not been studied previously in the Turkish population.
Materials and Methods: We examined PTEN protein expression immunohistochemically and its significance
in 69 primary prostate cancer patients from Turkey. Two tissue microarrays constructed by 0.6 mm cores
from radical prostatectomy specimens were used. Clinical information for all patients was obtained from
hospital records.
Results: PTEN loss was found in 49% of the tumors (P < 0.001). Down-regulation was also prevalent in
atrophic epithelium (58.7%) and in the inflamed non-neoplastic tissue (76.5%) (P < 0.001). Decreased PTEN
was prone to segregate with unfavorable prognostic features; however, a statistically significant correlation
could be obtained only with respect to the presence of positive surgical margins (P = 0.007).
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Conclusions: Alterations in PTEN protein level occur frequently in primary prostate cancers in Turkish men,
which can be a potential predictor of adverse features for outcome. Further studies with a larger cohort of
patients are needed to clarify its prognostic significance. High rate of loss of tumor suppressor PTEN in
atrophy and inflammation must provoke active research to clarify a possible connection of chronic
inflammation-atrophy with carcinogenesis in the prostate.
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Türk Hastalarda Primer Prostat Karsinomunda PTEN Ekspresyonu
Amaç: Prostatik adenokarsinom dünyada değişik coğrafi bölgeler ve ırklar arasında insidans ve biyolojik
davranım açısından belirgin farklılıklar göstermektedir. Bu durumu açıklayabilecek spesifik nedenler büyük
oranda gizli kalmıştır. PTEN ekspresyonu farklı organlardan köken alan birçok malignite türünde
bozulmuştur. Bu genin prostat kanserinde en sık mutasyon gösteren tümör supresör gen olduğu
bildirilmektedir. Şimdiye dek Türk popülasyonunda PTEN değişikliklerinin insidansı araştırılmamıştır.
Yöntem ve Gereç: Altmış dokuz Türk prostat karsinom olgusunda PTEN protein ekspresyonu ve ekspresyon
değişikliklerinin önemi immünohistokimyasal yöntemle araştırıldı. Bunun için radikal prostatektomi
spesmenlerinden alınan 0,6 mm.lik kor’larla oluşturulan iki doku mikrodizimi kullanıldı. Hastaların klinik
bilgilerine hastane kayıtlarından ulaşıldı.
Bulgular: PTEN kaybı tümörlerin % 49’unda saptandı (P < 0.001). Gen ekspresyonunda baskılanma atrofik
prostat epiteli (% 58.7) ve inflame non-neoplastik dokuda da mevcuttu (% 76.5) (P < 0.001). Azalmış PTEN,
olumsuz prognostik parametrelerle birlikte olma eğilimi gösterdi, ancak bu doğrultuda istatistik olarak anlamlı
korrelasyon yalnızca cerrahi sınır pozitifliği ile saptandı (P = 0.007).
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Sonuç: PTEN protein seviye değişikliklerine Türk hastalardaki primer prostat kanserinde sık olarak
rastlanmaktadır. Protein ekspresyonunda azalma kötü prognoza işaret eden bir belirleyici olma
potansiyelindedir. Prognostik öneminin aydınlatılması için daha geniş serilerle yürütülecek çalışmalara ihtiyaç
vardır. Tümör supresör bir gen olan PTEN’in atrofi ve inflamasyonda da yüksek oranda kaybı, prostatta kronik
inflamasyon ve atrofi ile karsinogenez arasındaki ilişkinin açığa çıkarılması yönündeki aktif çalışmaları
tetiklemelidir.
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Introduction
There is large variability in the incidence and biological
behavior of clinically manifest prostate carcinoma
between different races and geographical regions. It is
much rarer in East and Southeast Asia with respect to
western countries (1,2), which cannot be explained solely
by serum PSA screening. African-American patients
present with a more advanced stage disease compared
with Caucasian patients. The underlying reasons for these
differences have been unclear for decades. Genetic and
environmental factors including infections, different
hormonal milieu and diet have been suspected. Cancer
statistics are not fully satisfactory in Turkey.
Nevertheless, the age-adjusted incidence of prostate
carcinoma is estimated roughly as 8 per 100,000 among
Turkish men (3), which is considerably less frequent than
in western and northern Europe and North America.
Phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) is a tumor suppressor gene,
mapped to 10q 23.31, which functions in regulating the
signaling of multiple biological processes such as
apoptosis, metabolism, cell proliferation and cell growth.
Mutations of the PTEN have been detected in cancers of
various organs including the prostate (4-9). It is thus far
the most frequently mutated gene and its mutation is
associated with tumorigenesis in the prostate. To the best
of our knowledge, the frequency of altered PTEN in
prostate cancer in Turkish men has not yet been studied.
In this study, we aimed to determine the incidence of
PTEN loss immunohistochemically in a group of clinically
localized prostatic adenocarcinoma patients from Turkey.
Presence of any correlation between PTEN expression
and clinicopathological prognostic parameters was also
evaluated.

Materials and Methods
Patients and Prostate Specimens
A total of 69 clinically localized prostate carcinoma
patients who had undergone radical prostatectomy
between 1992 and 2001 were included in this study.
Sixty-nine cases had pelvic lymphadenectomy. No patient
had received androgen deprivation or radiotherapy for
cancer before surgery. Pre-operative data were collected
on all patients from the hospital charts.
388
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All slides for each case were retrieved from the
pathology archives and were reviewed by a single
pathologist (D. E. B.). Prognostically well-established
pathological parameters including Gleason score, status
of extraprostatic extension, seminal vesicle invasion,
surgical margins, lymphovascular invasion, lymph node
metastases and pathologic stage (pT) were noted. Tumor
volume was estimated by simple eye-balling.
Array Construction and Tissue Sections
The index tumor was identified in all radical
prostatectomies. The clinically most significant cancer
nodule was chosen as the index tumor, which was the
largest tumor focus with the highest Gleason score and
stage in all cases. Two tissue microarrays were
constructed by 0.6 mm tissue cores from 69 radical
prostatectomies using a manual tissue arrayer (Beecher
Instruments, Silver Spring, MD). They contained four
cores from the index tumor and an additional four cores
from corresponding non-neoplastic regions for each case.
Internal controls were placed in a preestablished pattern
throughout each array. Five-micrometer sections from
the array blocks and tissues were cut for hematoxylin
and eosin (H-E) and immunostaining. H-E sections were
reviewed to record the tissue type (unremarkable normal
glands, non-neoplastic glands surrounded by chronic
inflammation, atrophy, prostatic intraepithelial neoplasia
and adenocarcinoma) represented in each core.
Immunohistochemistry
Sections were deparaffinized and rehydrated. They
were then heated in citrate buffer steam (0.01 M, pH
8.0) for 20 min for antigen retrieval. Endogenous
peroxidase in sections was inactivated in 2% H2O2 for 10
min. The sections were then blocked in 3% normal horse
serum in 0.2 M phosphate buffered saline (PBS) (pH
7.4), followed by incubation with rabbit anti-PTEN
antibody from Zymed (San Francisco). Anti-PTEN was
used at a dilution of 1:8000 in PBS with 0.5% normal
horse serum. Sections were incubated overnight in
primary antibody at 4°C. They were then processed
following a standard ABC immunostaining (Vector
Laboratory, Burlingame, CA). Immunoreactive products
were visualized using 3,3’-diaminobenzidine.
Quantitation of Immunohistochemistry
PTEN immunostaining was evaluated microscopically
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for all tissue cores in the tissue microarrays. The
percentage of PTEN-positive cells (labeling frequency %)
as well as intensity seen at low power (graded as 0 to 3,
where 0 was defined as lack of staining, 1 weak staining,
2 moderate staining, and 3 intense staining) were
recorded. The extent of staining per core was stratified
into three groups based on the percentage of positive
cells: Group 1, < 25%; Group 2, 25 to 50%; and Group
3, >50%. Semiquatitative scores ranging from 1 to 9 for
the specific staining in the represented tissue type
(normal glands, normal glands with adjacent
inflammation, atrophy, prostatic intraepithelial neoplasia
or carcinoma) in each core were obtained by multiplying
the staining intensity by the number of the group
reflecting the percentage of positive cells. The labeling
index (LI), as the function of labeling frequency and
labeling intensity, was accepted as 1 for scores of 1 and
2, as 2 for scores of 3 and 4 and as 3 for scores of 6 and
9. Separate LIs were obtained for each tissue type
available in a specimen. Results from the cores belonging
to the same specimen were combined to reach one LI for
each case.
The majority of normal prostatic epithelium expressed
PTEN strongly and diffusely, >75% having LI of 2 and 3.
Based on this observation, absence of staining (LI = 0)
and LI at the level of 1 were considered as reduced PTEN
expression.
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Statistical Analysis
The differences in PTEN labeling were compared
between normal prostate, atrophy and cancer specimens
by using the Mann-Whitney test. The relationship of
PTEN expression with patients’ clinical and pathological
variables was evaluated using Fisher’s exact and chisquare tests for categorical variables and the
Mann–Whitney U test for continuous variables. P < 0.05
was taken to indicate statistical significance.

Results
Age of the patients varied between 48 and 75
(average and median: 62). PSA at diagnosis ranged from
1.3 to 41.5 ng/ml (mean: 11.68 ng/ml). Pelvic lymph
node metastasis was detected in 5 patients.
Extraprostatic extension, seminal vesicle invasion,
lymphovascular involvement and positive surgical margins
were identified in 67.6%, 24.6%, 14.5% and 45.6% of
the radical prostatectomies, respectively. Grade and stage
characteristics of the cases are displayed in Table 1.
PTEN Expression
Four hundred eighty-eight tissue cores were evaluated
in the two tissue microarrays. Of these, 245 represented
the tumor (belonging to 69 cases). Non-neoplastic
epithelium was present in 63 cases (total 239 cores,
among which 46 represented atrophy). An additional 4

Table 1. Distribution of 69 cases in the arrays according to tumor stage (pT) and Gleason score.
Gleason score*
Pathological Stage

pT2

pT3a

pT3b

Total

Total
6

7

8 or > 8

N0

11

8

2

21

NX

1

0

0

1

N0

5

14

9

28

N1

0

2

0

2

N0

0

11

2

13

N1

0

2

1

3

NX

0

0

1

1

17

37

15

22

30

17

69

* Grading based on radical prostatectomy specimen.
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cores represented high-grade prostatic intraepithelial
neoplasia belonging to 4 different patients.
The secretory layer of normal prostatic glands showed
high LI in the majority. Atrophy and inflammation led to
decrease in the intensity and the extent of staining.
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The intensity of staining in the normal-appearing
epithelium could be classified as moderate to strong with
LI of 3 or 2 in 75.5% of the tissue cores (Table 2). The
PTEN immunoreactivity was predominantly localized to
the secretory cells of normal prostatic glands (Figure 1).

Table 2. PTEN labeling index for different tissue types.
PTEN Labelling Index
Tissue Type (Number of cores)
0

1

2

3

Normal prostatic glands
(176)

38
(21.5%)

5
(3%)

9
(5%)

124
(70.5%)

Atrophic prostatic glands
(46)

24
(52.2%)

3
(6.5%)

2
(4.3%)

17
(37%)

Prostatic epithelium in inflammation
(17)

12
(70.6%)

1
(5.9%)

3
(17.6%)

1
(5.9%)

Prostatic carcinoma glands
(245)

123
(50.25%)

10
(4%)

17
(6.95%)

95
(38.8%)

Figure 1. Normal prostatic tissue from three patients. Staining reveals high PTEN protein levels
in luminal cells of prostate glands. Basal cells are generally negative.
(Immunohistochemistry, anti-PTEN Ab, ABC; a: x 100, b: x 400, c: × 1000).
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Basal cells and stromal cells were generally negative. With
regard to subcellular localization, PTEN staining was in
the cytoplasm. There was a noticeable reduction in
cytoplasmic PTEN in tumor tissues compared with the
staining in non-neoplastic normal looking glands (P <
0.001) (Figure 2). Reduced or loss of PTEN was
observed in 54.25% of 245 tumor cores (34 cases).
Among the 4 cores representing high-grade prostatic
intraepithelial neoplasia, 3 had no PTEN expression. Low
LI was also detected in atrophy or when non-neoplastic
glands were associated with inflammation (Figures 3-6).
Twenty-seven of 46 (58.7%) cores of atrophy and 13/17
(76.5%) cores of inflammation showed negative or low
levels of PTEN (both P values < 0.001).
Correlation
of
PTEN
Clinicopathologic Parameters

Expression

with

Age and pre-operative PSA level did not differ between
normal and reduced PTEN groups. Decreased PTEN
expression was more frequent in cases with unfavorable
prognostic features (Table 3). Of the 34 cases with low LI
for PTEN, 72.7% showed extraprostatic extension,
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29.4% seminal vesicle invasion, 61.8% positive surgical
margins, 20.6% lymphovascular involvement and 9%
lymph node metastasis. These ratios were 62.6%, 20%,
29.4%, 8.6% and 5.1%, respectively, in tumors with
normal PTEN expression. The size of the cohort possibly
was not sufficient for meaningful statistical figures. The
only correlation that reached statistical significance was
between reduced expression and positive surgical margins
(P = 0.007). No association was found between PTEN
expression and Gleason scores or PTEN expression and
pathological stage.

Discussion
Phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) is a dual function enzyme with
protein/lipid phosphatase activity, and its main substrate
is phosphatidyl-inositol 3,4,5 triphosphate (PIP3), a
direct product of phosphoinositol-3-kinase (10). Increase
in PIP3 recruits serine-threonine kinase AKT to the
membrane. AKT promotes cell survival and proliferation.
The role of PTEN is to maintain low levels of PIP3.

Figure 2. Markely reduced PTEN in prostatic adenocarcinoma. Normal glands display high
staining intensity. (Immunohistochemistry, anti-PTEN Ab, ABC; a: × 200, b: × 400).
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Figure 3. Two different cases in the array where normal and atrophic tissues from the same
specimen are represented in the adjacent cores. No staining is evident in atrophy in
either. (Immunohistochemistry, anti-PTEN Ab, ABC × 100).

Figure 4. Atrophic glands with reduced PTEN in the form of low intensity or patchy staining.
(Immunohistochemistry, anti-PTEN Ab, ABC; a: × 200; b: × 400).
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Figure 5. Two cores from the same case. Strong PTEN expression in normal glands when
stroma is unremarkable (left core). Glands lose the expression when the stroma is
inflamed (right core and lower picture). (Immunohistochemistry, anti-PTEN Ab, ABC;
a: × 100; b: × 200).

Figure 6. The inflammatory cells in the stroma and glandular lumina are associated with
decreased PTEN expression (Immunohistochemistry, anti-PTEN Ab, ABC × 400).
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Table 3. Distribution of cases according to prognostic factors and PTEN expression.
PTEN Expression
Variables

Gleason score

Extraprostatic extension

Seminal vesicle invasion

Surgical margins*

Pathological stage

Lymph node metastasis

Lymphovascular invasion

n: number of cases; * P = 0.007.
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Decreased
n (%)

Normal
n (%)

Total

6

8
(47.1%)

9
(52.9%)

17

7

17
(45.9%)

20
(54.1%)

37

>8

9
(60.0%)

6
(40.0%)

15

Absent

9
(40.9%)

13
(59.1%)

22

Present

24
(52.2%)

22
(47.8%)

46

Absent

24
(46.1%)

28
(53.90%)

52

Present

10
(58.9%)

7
(41.1%)

17

Positive

13
(35.1%)

24
(64.9%)

37

Negative

21
(67.7%)

10
(32.3%)

31

pT2

9
(40.9%)

13
(59.1%)

22

pT3a

15
(50%)

15
(50%)

30

pT3b

10
(58.8%)

7
(41.2%)

17

Absent

30
(48.4%)

32
(51.6%)

62

Present

3
(60.0%)

2
(40.0%)

5

Absent

27
(45.8%)

32
(54.2%)

59

Present

7
(70.0%)

3
(30.0%)
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Oncogenic effect of PTEN loss can be attributed to AKT
activation. Additional PTEN-regulated pathways have also
been identified as the genes associated with JNK
activation (11).
PTEN mutations are among the most frequent genetic
alterations detected in human prostate cancers. Our
finding of reduced PTEN expression at the protein level in
34 (49%) of 69 primary prostate cancer specimens
confirms that PTEN is one of the major genes in the
prostatic malignancy. Its critical role has been evidenced
by many studies. In PTEN heterozygous mice,
precancerous lesions were found and when both alleles
were deleted, cancer progression and metastasis occurred
(12). PTEN negatively regulates prostatic basal cell
proliferation (without blocking differentiation) and
concomitant expansion of a prostate stem/progenitor-like
subpopulation (13). Adenoviral vector-expressed PTEN
strongly inhibits the growth of xenograft human prostate
tumors in athymic mice, especially when combined with
radiation therapy (14). Knocking down PTEN can convert
the androgen-dependent Myc-CaP cell into androgen
independence, suggesting intrinsic control of androgen
responsiveness by PTEN (12). Androgen independence
has been found to associate with activation of the
phosphoinositide-3 kinase/Akt as well as Erk mitogenactivated protein kinase signaling pathways in the
prostate epithelium (15). It has been shown that silencing
Akt in PTEN-mutated prostate cancer cells enhances the
antitumor effects of taxol (16).
Mutation frequencies of PTEN in prostate cancer
differ among studies, largely because of differences in
tumor grade and stage in the study populations. Loss of
heterozygosity has been shown to occur in a range of
14% to 65% according to different reports (7,17-20).
Immunohistochemical PTEN protein expression was weak
in 24 of 58 primary prostate carcinomas (41.3%) and
negative in 8 (13.8%) in the study of Fenic et al. (21).
Halvorsen et al. (22) found lack of PTEN protein
expression in 27% and McMenamin et al. (23) in 20% of
cases. A 49% incidence of decreased PTEN expression at
the protein level in primary prostate cancers in Turkish
patients was similar to that observed in the German
population in the study of Dreher et al. (24), in which
they reported a 39% rate. These results suggest that
PTEN is not a genetic factor contributing to the racial
difference in prostate cancer incidence and that genetic
pattern is similar in terms of its mutation frequency.
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Loss of PTEN expression has been shown to correlate
with unfavorable prognosis in primary prostate cancer.
Patients with prostatic carcinoma who had PTEN
mutation had significantly greater Gleason score, poorer
prognosis, and higher rate of metastasis (23,25,26). In
one study, loss of PTEN expression at first time diagnosis
was 23%, while this was 59% in patients with lymph
node metastasis, a finding demonstrating that loss of
PTEN expression is an important factor in progression
towards metastatic disease (27). Results in regard to
PTEN loss as a predictor of disease progression are
controversial. Some have stated that it acts as an
independent indicator of biochemical recurrence after
radical prostatectomy (26), whereas others cannot
demonstrate this relation (25). In the series of Bedolla et
al., PTEN was a predictor of the risk of biochemical
recurrence if combined with pAkt while by itself it was
not (28).
In our data set, we found that reduced PTEN was
more frequent with worse prognostic factors. Rate of
PTEN reduction was higher among the cases who showed
extraprostatic extension, seminal vesicle involvement,
positive surgical margins and lymphovascular invasion.
However, size of our cohort was too small to give
meaningful statistical results. The only statistical
significance was obtained between surgical margin
positivity and low PTEN level (P = 0.007). The loss of
PTEN in multiple other tumor types has also been linked
to advanced disease and poor patient outcome (29, 30).
One of our findings was the high frequency of reduced
PTEN in atrophic prostatic glands. We observed PTEN
loss at a rate of 58.7% in atrophy. This was even more
apparent, reaching 76.5%, when there was associating
chronic inflammation in stroma. These results evoke the
question of the relationship between neoplastic
transformation and inflammation/atrophy. In fact, about
20% of all human cancers are caused by chronic infection
or chronic inflammatory states, including cancer of the
liver, stomach, large intestine, biliary tree and urinary
bladder. Cyclooxygenase-2 (COX-2) and 5-lipoxygenase
(5-LOX) enzymes are overexpressed during inflammation
and may contribute to multistage tumor development. It
has been reported that PTEN is oxidized and inactivated
during arachidonic acid metabolism in pancreatic cancer
cell lines expressing COX-2 or 5-LOX (31). Oxidation of
PTEN decreases its phosphatase activity, favoring
elevated
phosphatidylinositol
3,4,5-triphosphate
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production and activation of AKT, which increases the
risk for hypertrophic or neoplastic diseases. Molecular,
histopathological, and epidemiological studies show that
chronic inflammation might also be important in prostate
carcinogenesis. The inflammation and following epithelial
cellular injury may cause a loss of tolerance to normal
prostatic antigens, resulting in a self-perpetuating
autoimmune reaction. Chronic inflammatory infiltrates in
the prostate are associated with focal epithelial atrophy,
and atrophic epithelium displays many genetic alterations
such as methylated GSTP1 in 6% (32), increases in
chromosome 8 centromere signals (33, 34), loss of
chromosome 8p (34, 35) and a gain of chromosome
8q24 (34), downregulated tumor suppressor genes p27
(36, 37), and NKX3.1 (38) in focal atrophy, and mutated
p53 (39) and androgen receptor alleles (40) in postatrophic hyperplasia. Transitions between atrophic
epithelium and adenocarcinoma have been observed
morphologically by several investigators (32, 41, 42).

Turk J Med Sci

High rate of tumor suppressor PTEN protein reduction in
our atrophic and inflamed prostatic tissues can be
additional support for future studies that will target
investigating the pathogenetic link between inflammatory
atrophy and prostate carcinogenesis.
Our results indicate that PTEN loss is a common
alteration in sporadic prostate cancer irrespective of
different races, and it can be a universal genetic marker
for predicting disease progression. Genetic studies in
human tumors including documentation of the incidence
and significance of various mutations are warranted since
they will open the door for more effective disease
treatment and patient management strategies.
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